ImmaticsIMTX
IMTX
About: Immatics NV is a biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies.
Employees: 423
0
Funds holding %
of 7,425 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
42% more repeat investments, than reductions
Existing positions increased: 34 | Existing positions reduced: 24
3.69% more ownership
Funds ownership: 73.62% [Q3] → 77.31% (+3.69%) [Q4]
7% less funds holding
Funds holding: 91 [Q3] → 85 (-6) [Q4]
18% less call options, than puts
Call options by funds: $4.26M | Put options by funds: $5.19M
24% less capital invested
Capital invested by funds: $866M [Q3] → $656M (-$210M) [Q4]
26% less first-time investments, than exits
New positions opened: 17 | Existing positions closed: 23
50% less funds holding in top 10
Funds holding in top 10: 2 [Q3] → 1 (-1) [Q4]
Research analyst outlook
We haven’t received any recent analyst ratings for IMTX.
Financial journalist opinion
Neutral
GlobeNewsWire
5 days ago
Immatics Announces Upcoming Oral and Poster Presentation on IMA203 TCR T-cell Therapy at 2025 ASCO Annual Meeting
Houston, Texas and Tuebingen, Germany, April 23, 2025 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, today announced upcoming presentations on its lead cell therapy product candidate, IMA203 TCR T-cell therapy targeting PRAME, at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting to be held from May 30 – June 3, 2025, in Chicago, Illinois.
Negative
Seeking Alpha
1 month ago
Immatics N.V.: Trading Below Cash, But Not Without Reason
Immatics' lead asset, IMA203, shows promising early data with a 57% ORR in heavily pretreated patients, but toxicity concerns remain. Financially, IMTX has a $540mn market cap and $628mn cash, but negative enterprise value due to early-stage data and long catalyst desert. Phase 3 trial for IMA203 will produce interim data in early 2026, with no clear topline data timeline, creating uncertainty.
Neutral
GlobeNewsWire
1 month ago
Immatics Announces Full Year 2024 Financial Results and Business Update
Houston, Texas and Tuebingen, Germany, March 27, 2025 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, today provided a business update and reported financial results for the quarter and full year ended December 31, 2024.
Positive
Zacks Investment Research
2 months ago
New Strong Buy Stocks for February 12th
BOH, AUB, BHRB, IMTX and RH have been added to the Zacks Rank #1 (Strong Buy) List on February 12, 2025.
Positive
Zacks Investment Research
3 months ago
New Strong Buy Stocks for January 9th
AFRM, ZNTL, IMTX, MRCY and DRRX have been added to the Zacks Rank #1 (Strong Buy) List on January 9, 2024.
Positive
Zacks Investment Research
3 months ago
Immatics (IMTX) Upgraded to Buy: What Does It Mean for the Stock?
Immatics (IMTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Positive
Zacks Investment Research
5 months ago
What Makes Immatics (IMTX) a New Buy Stock
Immatics (IMTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Negative
Zacks Investment Research
5 months ago
Immatics (IMTX) Reports Q3 Loss, Tops Revenue Estimates
Immatics (IMTX) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to loss of $0.35 per share a year ago.
Neutral
GlobeNewsWire
5 months ago
Immatics Announces Third Quarter 2024 Financial Results, Business Update and First Clinical Data on TCER® IMA402 Targeting PRAME
The Company will now target five major cancer types with its four clinically active compounds across both TCR-T cell therapies and TCR-based Bispecifics
Neutral
GlobeNewsWire
5 months ago
Immatics Announces Multiple Presentations at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) on TCR-T Therapy Candidates Targeting PRAME
Two oral presentations and multiple posters on clinical and preclinical-stage candidates to be presented at SITC, demonstrating the strength of Immatics' TCR-T PRAME franchise to target solid cancers
Charts implemented using Lightweight Charts™